Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024

The global proliferative diabetic retinopathy (pdr) market has grown rapidly in recent years. It will grow from $2.16 billion in 2023 to $2.42 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The global proliferative diabetic retinopathy (pdr) market is expected to see rapid growth in the next few years. It will grow to $3.62 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (ai) for early diagnosis, gene therapy advancements, advanced retinal imaging.

The increasing prevalence of diabetes is anticipated to be a significant driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Diabetes, a chronic medical condition characterized by elevated blood glucose levels, stands as the primary contributor to proliferative diabetic retinopathy. Various treatments are available to prevent further damage to the retina and preserve vision in individuals with diabetes. For instance, as reported by the International Diabetes Federation (IDF), a Belgium-based organization, the year 2021 witnessed 537 million adults between the ages of 20-79 affected by diabetes, which translates to 1 in 10 people. This number is projected to increase to around 643 million by 2030 and further to 783 million by 2045. As a result, the rising prevalence of diabetes serves as a driving force behind the growth of the proliferative diabetic retinopathy (PDR) market.

The increasing prevalence of obesity is expected to be a key driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Obesity, a multifaceted, chronic condition with various contributing factors, results in an excess accumulation of body fat and potential health issues. Obesity is closely associated with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress, all of which can adversely affect the retinal microvasculature and contribute to the onset of diabetic retinopathy. For instance, according to a 2022 report released by Trust for America's Health, a non-profit organization in the United States, obesity rates in the country are on the rise, with four out of every ten American adults being affected by obesity. This represents an increase compared to the previous year, with 19 states reporting adult obesity rates exceeding 35%, up from 16 states in the preceding year. Consequently, the escalating prevalence of obesity serves as a pivotal catalyst driving the expansion of the proliferative diabetic retinopathy (PDR) market.

High treatment costs serve as a deterrent to the growth of the proliferative diabetic retinopathy (PDR) market during the projected period. The expenses associated with diagnosing and treating PDR can pose a significant financial burden, often reaching prohibitive levels. This encompasses the costs related to frequent eye examinations, laser therapy, and, in certain cases, surgical interventions. These elevated treatment expenses create financial challenges for both patients and healthcare systems. For instance, in 2023, as reported by Medical News Today, individuals typically face annual management costs ranging from $600 to $1,000 for the treatment of diabetic eye disease, while the cost of a vitrectomy procedure falls within the range of $8,000 to $14,000. As a result, the high treatment costs emerge as a constraining factor, impeding the growth of the proliferative diabetic retinopathy (PDR) market.

Prominent companies operating in the proliferative diabetic retinopathy market maintain a consistent focus on the development of groundbreaking therapies. This strategic emphasis aims to enhance treatment efficacy, alleviate the treatment-related financial burden, and ultimately elevate patient outcomes. For instance, in June 2022, Biogen, a leading US-based biotechnology company, partnered with Samsung Bioepis, a South Korea-based biotech company, to introduce Byooviz (ranibizumab-nuna). Byooviz represents the first ophthalmology biosimilar in the United States, offering treatment options for patients dealing with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization. These innovative therapies are poised to bring transformative changes to the landscape of proliferative diabetic retinopathy treatment.

In September 2021, AbbVie, a pharmaceutical company based in the United States, and REGENXBIO Inc. entered into a collaborative partnership, the financial details of which have not been disclosed. This strategic alliance is driven by a shared objective includes the development and commercialization of RGX-314, a potential one-time gene therapy specifically crafted to address conditions like wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. At present, RGX-314 is undergoing a pivotal trial focused on wet AMD, employing a subretinal administration approach. Simultaneously, separate Phase II clinical trials are underway for both wet AMD and DR, with the utilization of in-office suprachoroidal delivery. Notably, REGENXBIO Inc., a US-based company renowned for its work in developing treatments for proliferative diabetic retinopathy (PDR), plays an integral role in this collaborative effort.

Major players in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

North America was the largest region in the proliferative diabetic retinopathy market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the proliferative diabetic retinopathy (PDR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary treatment options for proliferative diabetic retinopathy encompass anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery, and vitrectomy. Intraocular steroids involve the direct administration of medications into the eye, which serves to address inflammation and manage conditions like diabetic macular edema or uveitis. This approach aids in reducing swelling and enhancing visual outcomes. Various modes of administration, including injectables, oral medications, and others, find application in settings such as hospitals, clinics, and more.

This report provides proliferative diabetic retinopathy market statistics, including proliferative diabetic retinopathy industry global market size, regional shares, competitors with a proliferative diabetic retinopathy market share, detailed proliferative diabetic retinopathy market segments, market trends and opportunities and any further data you may need to thrive in the proliferative diabetic retinopathy industry. This proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.